In terms of BAFF and APRIL, two different blocking options are currently available for autoimmune diseases, such as the anti-BAFF monoclonal antibody and a recombinant fusion protein containing a receptor (i.g., transmembrane activator and CAML interactor) fused to the Fc portion of immunoglobulin [16, 17]. This evidence concerns the gene CAMLG and autoimmune disease.